Core Viewpoint - The approval of China's first glioblastoma electric field therapy system marks a significant breakthrough in the treatment of high-difficulty brain tumors, enhancing survival rates for patients [1][2] Group 1: Product Approval and Impact - The electric field therapy system has received approval from the National Medical Products Administration, representing a major advancement in the field of brain tumor treatment [1] - Clinical trials indicate that for newly diagnosed glioblastoma patients, the median survival time can be extended from approximately 15 months to 31.11 months when combined with standard surgery and radiochemotherapy [1] - The median progression-free survival time reached 12.91 months, showcasing the effectiveness of the treatment [1] Group 2: Treatment Methodology and Benefits - The treatment is a non-invasive physical method that does not affect the patient's quality of life and avoids the side effects associated with traditional drug therapies [1] - The system allows for home treatment, significantly improving treatment adherence and preserving the dignity of patients [1] Group 3: Market and Accessibility - The high cost of imported electric field therapy devices, often exceeding one million yuan annually, has previously limited access for most patients [2] - The successful launch of the domestic device is a result of a nine-year collaborative effort among domestic "production, learning, research, and medical" teams, achieving complete autonomy from core technology to clinical application [2] - The introduction of this domestic product is expected to lower treatment costs and significantly enhance accessibility for patients [2] Group 4: Future Developments - A new generation of personalized precision electric field therapy based on genomics is currently in preclinical research, promising to further improve treatment efficacy in the future [2] - The clinical trial was led by the Capital Medical University affiliated Beijing Tiantan Hospital, with participation from 11 medical institutions, indicating a strong collaborative effort in the medical community [2]

Core Insights - The tumor electric field therapy system developed in China has received approval from the National Medical Products Administration, marking a significant breakthrough in the treatment of glioblastoma, a highly malignant brain tumor, and breaking the long-standing foreign technological monopoly [1][2] Group 1: Product Approval and Clinical Trials - The electric field therapy system is the first of its kind in China and the second globally for glioblastoma treatment, based on a pivotal Phase III clinical trial led by Beijing Tiantan Hospital and involving 11 top medical institutions [1][3] - The trial results indicate that for newly diagnosed glioblastoma patients, the median overall survival (mOS) can be significantly extended from approximately 15 months to 31.11 months when combined with standard surgery and radiochemotherapy [1] Group 2: Treatment Benefits and Accessibility - The non-invasive nature of the treatment allows for home-based therapy, improving patient compliance and quality of life while avoiding the side effects associated with traditional drug treatments [2] - The successful launch of this domestic product is expected to drastically reduce treatment costs, which previously exceeded one million yuan annually for imported products, thereby enhancing accessibility for patients [2] Group 3: Future Developments - A new generation of personalized electric field therapy based on genomics is currently in preclinical research, aiming to further optimize treatment efficacy through tailored approaches [2]